GANSU LONGSHENRONGFA PHARMACEUTICAL INDUSTRY CO.,LTD Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Stock
Equities
300534
CNE100002CP5
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.89 CNY | +0.90% |
|
-3.66% | -20.06% |
| Sales 2022 | 413M 57.04M | Sales 2023 | 1.08B 149M | Capitalization | 2.99B 413M |
|---|---|---|---|---|---|
| Net income 2022 | 25M 3.45M | Net income 2023 | 61M 8.42M | EV / Sales 2022 | 6.27 x |
| Net cash position 2022 | 97.83M 13.5M | Net cash position 2023 | 144M 19.93M | EV / Sales 2023 | 2.64 x |
| P/E ratio 2022 |
104
x | P/E ratio 2023 |
48.6
x | Employees | 763 |
| Yield 2022 * |
-
| Yield 2023 |
0.2% | Free-Float | 59.9% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.90% | ||
| 1 week | -3.66% | ||
| Current month | -4.13% | ||
| 1 month | -1.00% | ||
| 3 months | -9.00% | ||
| 6 months | -28.66% | ||
| Current year | -20.06% |
1 week
7.71
8.05
1 month
7.718.71
Current year
6.3011.90
1 year
6.3012.36
3 years
5.2417.50
5 years
4.7617.50
10 years
4.7631.56
| Managers | Title | Age | Since |
|---|---|---|---|
Shuang Xi Qian
CEO | Chief Executive Officer | 39 | 23-03-09 |
Zheng Choi Zhao
DFI | Director of Finance/CFO | 37 | 09-06-30 |
Yong Hong Kang
BRD | Director/Board Member | 48 | 02-06-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qin Hui Yuan
BRD | Director/Board Member | 49 | 12-11-28 |
Zong Yi Li
BRD | Director/Board Member | 54 | 20-12-29 |
Kan Ren Zhou
BRD | Director/Board Member | 48 | 17-11-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 7.89 | +0.90% | 4,019,550 |
| 24-05-24 | 7.82 | +0.77% | 4,164,100 |
| 24-05-23 | 7.76 | -3.36% | 5,875,299 |
| 24-05-22 | 8.03 | +0.37% | 4,029,500 |
| 24-05-21 | 8 | -2.32% | 7,182,700 |
End-of-day quote Shenzhen S.E., May 26, 2024
More quotes
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd is a company mainly engaged in research and development, production and sales of Chinese traditional medicine. The Company operates two segments. The Pharmaceutical Manufacturing segments is involved in the production and sale of Chinese traditional medicine, health food and raw materials. Its primary product is Yuanhuzhitong dripping pills, which is used for the treatment of stomach pain, rib pain and headache. The Company also produces other drugs, including compound salvia miltiorrhiza tablets, anti-inflammatory and gallbladder tablets, as well as Sanqi injury tablets. The Sales and Logistics segment operates logistics and distribution business.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.06% | 330M | |
| +36.11% | 727B | |
| -6.90% | 354B | |
| +15.94% | 328B | |
| +0.21% | 277B | |
| +13.68% | 243B | |
| +7.41% | 205B | |
| -6.01% | 203B | |
| +4.23% | 164B | |
| -1.39% | 164B |
- Stock Market
- Equities
- 300534 Stock
